Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
In this retrospective study, we aimed to identify the risk factors for bleeding in patients after critical illness during edoxaban treatment. Data from patients who received edoxaban after critical illness at the Emergency Department at a tertiary care hospital were obtained from the hospital medica...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/3/860 |
| _version_ | 1797624126374936576 |
|---|---|
| author | Ryusei Mikami Mineji Hayakawa Shungo Imai Kunihiko Maekawa Kojiro Yamazaki Mitsuru Sugawara Yoh Takekuma |
| author_facet | Ryusei Mikami Mineji Hayakawa Shungo Imai Kunihiko Maekawa Kojiro Yamazaki Mitsuru Sugawara Yoh Takekuma |
| author_sort | Ryusei Mikami |
| collection | DOAJ |
| description | In this retrospective study, we aimed to identify the risk factors for bleeding in patients after critical illness during edoxaban treatment. Data from patients who received edoxaban after critical illness at the Emergency Department at a tertiary care hospital were obtained from the hospital medical records. Multivariate analysis revealed the risk factors for edoxaban-associated bleeding. Additionally, we developed an edoxaban-associated bleeding score (EAB score) based on these results. The derived EAB score was compared with the HAS-BLED score using receiver operating characteristic (ROC) curve analysis. Bleeding was observed in 42 of 114 patients (36.8%). We identified the following bleeding predictors (odds ratios, 95% confidence interval, score points) using multivariate analysis: concomitant use of antiplatelet agents (6.759, 2.047–22.32, 2 points), concomitant use of P-glycoprotein inhibitors (3.825, 1.484–9.856, 1 point), prothrombin time (PT)% following edoxaban administration of <75% and ≥60% (2.507, 0.788–7.970, 1 point), and PT% following edoxaban administration of <60% (11.23, 3.560–35.42, 3 points). The ROC curve analysis revealed an area under the curve of 0.826 for the EAB score and 0.625 for the HAS-BLED score. Under appropriate edoxaban dosing regimens in patients after critical illness, a combination of antiplatelet agents, P-gp inhibitors, and a low PT% following edoxaban administration were identified as strong risk factors for bleeding. |
| first_indexed | 2024-03-11T09:38:41Z |
| format | Article |
| id | doaj.art-2b1a4da89d364722bb7a311326c6352b |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T09:38:41Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-2b1a4da89d364722bb7a311326c6352b2023-11-16T17:08:14ZengMDPI AGJournal of Clinical Medicine2077-03832023-01-0112386010.3390/jcm12030860Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical IllnessRyusei Mikami0Mineji Hayakawa1Shungo Imai2Kunihiko Maekawa3Kojiro Yamazaki4Mitsuru Sugawara5Yoh Takekuma6Department of Pharmacy, Hokkaido University Hospital, Sapporo 060-8648, JapanDepartment of Emergency Medicine, Hokkaido University Hospital, Sapporo 060-8648, JapanFaculty of Pharmacy, Keio University, Tokyo 105-8512, JapanDepartment of Emergency Medicine, Hokkaido University Hospital, Sapporo 060-8648, JapanDepartment of Pharmacy, Hokkaido University Hospital, Sapporo 060-8648, JapanFaculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, JapanDepartment of Pharmacy, Hokkaido University Hospital, Sapporo 060-8648, JapanIn this retrospective study, we aimed to identify the risk factors for bleeding in patients after critical illness during edoxaban treatment. Data from patients who received edoxaban after critical illness at the Emergency Department at a tertiary care hospital were obtained from the hospital medical records. Multivariate analysis revealed the risk factors for edoxaban-associated bleeding. Additionally, we developed an edoxaban-associated bleeding score (EAB score) based on these results. The derived EAB score was compared with the HAS-BLED score using receiver operating characteristic (ROC) curve analysis. Bleeding was observed in 42 of 114 patients (36.8%). We identified the following bleeding predictors (odds ratios, 95% confidence interval, score points) using multivariate analysis: concomitant use of antiplatelet agents (6.759, 2.047–22.32, 2 points), concomitant use of P-glycoprotein inhibitors (3.825, 1.484–9.856, 1 point), prothrombin time (PT)% following edoxaban administration of <75% and ≥60% (2.507, 0.788–7.970, 1 point), and PT% following edoxaban administration of <60% (11.23, 3.560–35.42, 3 points). The ROC curve analysis revealed an area under the curve of 0.826 for the EAB score and 0.625 for the HAS-BLED score. Under appropriate edoxaban dosing regimens in patients after critical illness, a combination of antiplatelet agents, P-gp inhibitors, and a low PT% following edoxaban administration were identified as strong risk factors for bleeding.https://www.mdpi.com/2077-0383/12/3/860critical illnessanticoagulantedoxabanbleeding score |
| spellingShingle | Ryusei Mikami Mineji Hayakawa Shungo Imai Kunihiko Maekawa Kojiro Yamazaki Mitsuru Sugawara Yoh Takekuma Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness Journal of Clinical Medicine critical illness anticoagulant edoxaban bleeding score |
| title | Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness |
| title_full | Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness |
| title_fullStr | Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness |
| title_full_unstemmed | Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness |
| title_short | Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness |
| title_sort | prediction and implications of edoxaban associated bleeding in patients after critical illness |
| topic | critical illness anticoagulant edoxaban bleeding score |
| url | https://www.mdpi.com/2077-0383/12/3/860 |
| work_keys_str_mv | AT ryuseimikami predictionandimplicationsofedoxabanassociatedbleedinginpatientsaftercriticalillness AT minejihayakawa predictionandimplicationsofedoxabanassociatedbleedinginpatientsaftercriticalillness AT shungoimai predictionandimplicationsofedoxabanassociatedbleedinginpatientsaftercriticalillness AT kunihikomaekawa predictionandimplicationsofedoxabanassociatedbleedinginpatientsaftercriticalillness AT kojiroyamazaki predictionandimplicationsofedoxabanassociatedbleedinginpatientsaftercriticalillness AT mitsurusugawara predictionandimplicationsofedoxabanassociatedbleedinginpatientsaftercriticalillness AT yohtakekuma predictionandimplicationsofedoxabanassociatedbleedinginpatientsaftercriticalillness |